Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 11.59%
- Poor long term growth as Net Sales has grown by an annual rate of 1.07% and Operating profit at 7.02% over the last 5 years
- The company is Net-Debt Free
Stock DNA
Pharmaceuticals & Biotechnology
ILS 140,535 Million ()
10.00
NA
0.00%
1.67
32.32%
6.08
Revenue and Profits:
Net Sales:
12,282 Million
(Quarterly Results - Jun 2026)
Net Profit:
-1,705 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
879.67%
0%
879.67%
6 Months
1105.0%
0%
1105.0%
1 Year
1736.89%
0%
1736.89%
2 Years
382.0%
0%
382.0%
3 Years
708.72%
0%
708.72%
4 Years
136.0%
0%
136.0%
5 Years
102.52%
0%
102.52%
Teva Pharmaceutical Industries Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.07%
EBIT Growth (5y)
7.02%
EBIT to Interest (avg)
3.25
Debt to EBITDA (avg)
3.93
Net Debt to Equity (avg)
2.39
Sales to Capital Employed (avg)
0.71
Tax Ratio
0.88%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
13.72%
ROE (avg)
25.11%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
4.15
EV to EBIT
11.04
EV to EBITDA
8.85
EV to Capital Employed
2.23
EV to Sales
2.57
PEG Ratio
0.14
Dividend Yield
NA
ROCE (Latest)
20.19%
ROE (Latest)
41.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
12,282.20
12,454.40
-1.38%
Operating Profit (PBDIT) excl Other Income
1,177.90
3,115.90
-62.20%
Interest
781.30
670.60
16.51%
Exceptional Items
-1,083.20
-383.60
-182.38%
Consolidate Net Profit
-1,704.70
1,150.90
-248.12%
Operating Profit Margin (Excl OI)
37.80%
190.30%
-15.25%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -1.38% vs -18.95% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -248.12% vs -26.27% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
59,751.00
61,114.70
-2.23%
Operating Profit (PBDIT) excl Other Income
17,311.70
16,243.00
6.58%
Interest
3,245.70
3,483.30
-6.82%
Exceptional Items
-6,494.90
-13,944.20
53.42%
Consolidate Net Profit
4,891.00
-7,251.60
167.45%
Operating Profit Margin (Excl OI)
231.90%
201.60%
3.03%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -2.23% vs 4.56% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 167.45% vs -219.72% in Dec 2024
Footer loading






